The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug manufacturers.